Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Plos One|July 20, 2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaBonnie K Harrington, Heather L Gardner, Raquel Izumi, et al.
Science Immunology|June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
American Journal of Therapeutics|July 23, 2008
Design and rationale of the URGENT Dyspnea study: an international, multicenter, prospective studyPeter S Pang, Miguel Tavares, Sean P Collins, et al.
Surgical Endoscopy|January 12, 2022
Ursodeoxycholic acid for the prevention of gall stones after laparoscopic sleeve gastrectomy: a prospective controlled studyMohamed AbdAlla Salman, Ahmed Salman, Usama Shaker Mohamed, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Blood|December 27, 2019
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 resultsJohn C Byrd, William G Wierda, Anna Schuh, et al.
The Lancet. Haematology|December 24, 2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyRoger G Owen, Helen McCarthy, Simon Rule, et al.
Pageof 13